EFPIA Report Pinpoints Risks From EMA Relocation
A new 25-page report commissioned by the European Federation of Pharmaceutical Industries and Associations (EFPIA) has highlighted the serious risks posed to public health by the relocation of the European Medicines Agency (EMA). The relocation will restrict the agency’s ability to call on and manage the network of expertise it relies on and limit staff retention and capacity, warns the authors.
Compiled by the consulting firm Charles Rivers Associates, the study analyzes the range of activities undertaken by the EMA and considers the impact of the move on continuity, patients, and approval of new medicines.
The report identifies two key areas-the evaluation of applications for marketing authorization and monitoring the safety of medicines across their lifecycle-as having the most significant detrimental effect on public health due to the relocation.
Delays in evaluating applications for marketing authorization mean delays in access to new medicines for patients across Europe, while disruption to critical safety functions can lead to delays in identification, management, and communication of safety issues, thereby putting patients at risk, according to the authors.
Transitional arrangements must be put in place to ensure the EMA has the time to manage the relocation and safeguard public health, they stated.
"The EMA plays a key role in Europe's health, ensuring that medicines are safe, effective, and of high quality,” noted EFPIA Director General Nathalie Moll. “This report underlines the importance of both the location decision and transitional arrangements to the agency's future. Supporting the continuity of its critical functions, its ability to retain staff, and access expert networks is central to its future and to public health."
To download a copy of the report, click here.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
